Actinium Pharmaceuticals, Inc. Completes Technology Transfer For Manufacturing Of Its Lead Drug Candidate Iomab™-B
Published: Dec 19, 2013
NEW YORK--(BUSINESS WIRE)--Actinium Pharmaceuticals, Inc. (OTCQB:ATNM.OB) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, has successfully transferred the technology for the manufacture of Iomab™-B (BC8-I-131), a drug being developed for therapeutic treatment of incurable blood cancers. The Company now intends to complete plans to scale-up, submit an Investigational New Drug (IND) Application to the U.S. Food and Drug Administration and initiate a pivotal Phase 3 clinical trial in 2014.
Help employers find you! Check out all the jobs and post your resume.